For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.
Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and how patents can create perverse incentives to delay new and better drugs.
Guest: Rebecca Robbins, a business reporter covering the pharmaceutical industry for The New York Times.
Background reading:
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
Trump's 2024 Playbook
Baseball’s Plan To Save Itself From Boredom: An Update
A Mother, a Daughter, a Deadly Journey: An Update
Inside Russia’s Crackdown on Dissent: An Update
How A Paradise Became A Death Trap: An Update
Biden Supports Israel. Does the Rest of America?
The New State of the War in Gaza
Why a Colorado Court Just Knocked Trump Off the Ballot
Football’s Young Victims
The Man Who Counts Every Shooting in America
The Sunday Read: ‘Bariatric Surgery at 16’
The Year of Taylor Swift
The Woman Who Fought the Texas Abortion Ban
Antisemitism and Free Speech Collide on Campuses
Ukraine’s Counteroffensive Fizzled. U.S. Funding May Be Next.
Can an ‘Anarcho-Capitalist’ President Save Argentina’s Economy?
The Sunday Read: ‘The Bodily Indignities of the Space Life’
Biden Is Trying to Rein In Israel. Is It Working?
Nikki Haley’s Moment
Opioid Victims Have a Settlement. Will the Supreme Court Undo It?
Create your
podcast in
minutes
It is Free
Up First from NPR
Consider This from NPR
The World
The Ezra Klein Show
Today in Focus